investors & media

More events are coming soon.

corporate profile

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

11/7/2022

- Commercial launch of ZYNTEGLO® ( betibeglogene autotemcel ) underway; on track for first apheresis in the fourth quarter of 2022 - - Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash -

Read more
11/2/2022

SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 2, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 31 st Annual Credit Suisse Healthcare Conference , Tuesday, November 8 , at 5:00 p.m. PT at the Terranea Resort , Rancho Palos Verdes,

Read more
9/16/2022

SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease Management team to host conference call Monday, September 19 , at 8:00 a.m. ET SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep.

Read more